AKT1 and Sepsis: Hydralazine has also been suggested to inhibit AKT activation (as observed in an animal sepsis model [54]) and to reduce cleaved caspase-3 and caspase-9 levels (as shown in a rat model of cardiac injury [55]), and has been demonstrated to promote caspase-dependent apoptotic cell death in human leukemic T cells [17].